Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Joel D. Parry"'
Autor:
Piotr J. Kamola, Klio Maratou, Paul A. Wilson, Kay Rush, Tanya Mullaney, Tom McKevitt, Paula Evans, Jim Ridings, Probash Chowdhury, Aude Roulois, Ann Fairchild, Sean McCawley, Karen Cartwright, Nigel J. Gooderham, Timothy W. Gant, Kitty Moores, Stephen A. Hughes, Mark R. Edbrooke, Kenneth Clark, Joel D. Parry
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 8, Iss , Pp 383-394 (2017)
Antisense oligonucleotide (ASO) gapmers downregulate gene expression by inducing enzyme-dependent degradation of targeted RNA and represent a promising therapeutic platform for addressing previously undruggable genes. Unfortunately, their therapeutic
Externí odkaz:
https://doaj.org/article/b04a0634ef634c9784c5c5759a036d27
Autor:
Lauren Mihalcik, Patrik U. Andersson, Yann Tessier, Chidozie Amuzie, William E. Achanzar, Jonathan G. Moggs, Laurence O. Whiteley, Joel D. Parry
Publikováno v:
Nucleic Acid Therapeutics. 31:7-20
The Oligonucleotide Working Group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) conducted a survey of companies to understand the trends in nonclinical practices and regulatory expectations for oligonucleotide drug
Autor:
Klio Maratou, Tom McKevitt, Piotr J. Kamola, Aude Roulois, Kay Rush, Probash Chowdhury, Stephen A. Hughes, Kitty Moores, Timothy W. Gant, Paula Evans, Paul A. Wilson, Joel D. Parry, Mark R. Edbrooke, Jim Ridings, Ann Fairchild, Tanya M. Mullaney, Nigel J. Gooderham, Kenneth L. Clark, Sean J. McCawley, Karen Cartwright
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 8, Iss, Pp 383-394 (2017)
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids
Antisense oligonucleotide (ASO) gapmers downregulate gene expression by inducing enzyme-dependent degradation of targeted RNA and represent a promising therapeutic platform for addressing previously undruggable genes. Unfortunately, their therapeutic
Autor:
Donald Riley, Joanne Kamens, Saraswathy Nochur, Laurence O. Whiteley, Scott P. Henry, Steven R. Bartz, Husam S. Younis, Morten Lindow, Arthur A. Levin, Hans-Peter Vornlocher, Joel D. Parry, James D. Thompson, Douglas J. Kornbrust, Julja Burchard, Nicolay Ferrari
Publikováno v:
Nature Biotechnology. 30:920-923
Autor:
Aude Roulois, Deon Hildebrand, Tom McKevitt, Dave Hassall, Jeffrey K. Huang, S J Bolton, Joel D. Parry, Mary McFarlane, Stefano Pluchino, Rajni Fagg, Wolfgang Brück
Publikováno v:
Toxicologic Pathology. 40:122-125
Abbreviations: ASC, adult stem cell line; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; MS, multiple sclerosis; MSC, mesenchymal stem cell; NPCs, neural stem/precursor cells; OPCs, oligodendrocyte precursor cells; RNA, rib
Autor:
Jeremy D. A. Kitson, Kenneth L. Clark, Mark R. Edbrooke, Nigel J. Gooderham, Emma Koppe, William E. Wixted, Gaelle A. Douillard Guilloux, Linda C. Warnock, Joel D. Parry, Aliza Panjwani, Gemma Turner, Piotr J. Kamola, Paul A. Wilson, Klio Maratou, Stephen A. Hughes, Sofie Eriksson, Kitty Moores, Timothy W. Gant
Publikováno v:
Nucleic Acids Research
With many safety and technical limitations partly mitigated through chemical modifications, antisense oligonucleotides (ASOs) are gaining recognition as therapeutic entities. The increase in potency realized by 'third generation chemistries' may, how
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01232cad7ce261e9e3cf77f33d86c7c2
http://hdl.handle.net/10044/1/26355
http://hdl.handle.net/10044/1/26355
Autor:
Joel D. Parry, Joanne Kilgour, David G. Hassall, Mark Collinge, Chris Clarke, Kristen Nikula, Lea Ann Dailey, Ian Robinson, Matthew D. Reed, Joseph A. Dybowski, Curtis Maier, Raegan O'Lone, Ben Forbes, Rhys M. Jones, Deon Hildebrand, Alison Wolfreys, Lindsay Tomlinson, Anthony Cahn, Jan Klapwijk, Louise E. Donnelly, Philippa Pribul Allen, Tim McGovern
Publikováno v:
Advanced drug delivery reviews. 71
Alveolar macrophage (AM) responses are commonly induced in inhalation toxicology studies, typically being observed as an increase in number or a vacuolated ‘foamy’ morphology. Discriminating between adaptive AM responses and adverse events during
Autor:
Kitty Moores, Walter Strapps, Daren S. Levin, Stephen C. Hyde, Paul A. Wilson, Christopher J. Gruenloh, Stephen A. Hughes, Mark R. Edbrooke, Michael J. Carr, Jill Coates, Katja Sobczak, Wolf-Michael Weber, Victoria Pickering, Ian A. Pringle, Stephanie G. Sumner-Jones, Ruth J. Mayer, Deborah R. Gill, Jill Darton, Pallav A. Bulsara, Joel D. Parry, Vasant Jadhav, Kenneth L. Clark, Sharon Jamison, Lee A. Davies
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 2, Iss C (2013)
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids
Lung pathology in cystic fibrosis is linked to dehydration of the airways epithelial surface which in part results from inappropriately raised sodium reabsorption through the epithelial sodium channel (ENaC). To identify a small-interfering RNA (siRN
Autor:
Francis H. Y. Green, Stephen B. Shrewsbury, Joy Cavagnaro, Jeff Tepper, Homer A. Boushey, Paolo M. Renzi, Harald Renz, Holger Garn, Rosanne Seguin, Nicolay Ferrari, Eric W.F.W. Alton, Michael Hodges, Joel D. Parry, Richard J. Martin, Robert D. Murdoch, Graham Johnson
Publikováno v:
Nucleic acid therapeutics, vol 22, iss 4
Oligonucleotides (ONs) are an emerging class of drugs being developed for the treatment of a wide variety of diseases including the treatment of respiratory diseases by the inhalation route. As a class, their toxicity on human lungs has not been full
Autor:
Shu-Dong Zhang, Tracy Walker, Amy Pointon, Kate M. Phillips, Emma L. Marczylo, Joel D. Parry, Jonathan J. Lyon, Joan Riley, Jinli Luo, Timothy W. Gant
Publikováno v:
PLoS ONE
PLoS ONE, Vol 5, Iss 9, p e12733 (2010)
PLoS ONE, Vol 5, Iss 9, p e12733 (2010)
BackgroundDoxorubicin is one of the most effective anti-cancer drugs but its use is limited by cumulative cardiotoxicity that restricts lifetime dose. Redox damage is one of the most accepted mechanisms of toxicity, but not fully substantiated. Moreo